中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

21 records (took 0.02 seconds)

    CANCER DIAGNOSIS BASED ON LEVELS OF ANTIBODIES AGAINST GLOBO H AND ITS FRAGMENTS
    11.
    发明专利
    CANCER DIAGNOSIS BASED ON LEVELS OF ANTIBODIES AGAINST GLOBO H AND ITS FRAGMENTS 未知

    公开(公告)号：NZ590064A

    公开(公告)日：2012-05-25

    申请号：NZ59006409

    申请日：2009-06-16

    Applicant: ACADEMIA SINICA

    Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  WANG CHENG-CHI ,  YU ALICE L

    IPC: G01N33/574 ,  G01N33/53

    Abstract: A cancer diagnostic method that comprises the steps: (a) Providing a sample containing antibodies from a subject suspected of having cancer; (b) Incubating the sample with Gb5 and one or more of Globo H, Bb2, Bb3 and Bb4 to allow binding of the antibodies in the sample to the Gb5 and the Globo H, Bb2, Bb3 and Bb4; (c) Measuring the amount of the GB-5-bound antibodies and the amount of the Globo H-bound, Bb2-bound, Bb3-bound and Bb4-bound antibodies; (d) Determining whether the subject has the cancer based on the amounts of Gb5-bound antibodies and the Globo H-bound, Bb2-bound, Bb3-bound and Bb4-bound antibodies; The cancer is Globo H-positive and GB5-positive; and a higher ratio of the amount of Globo H-bound, Bb2-bound, Bb3-bound and Bb4-bound antibodies to the amount of Gb5-bound antibodies compared to a cancer-free subject indicates the subject has cancer. The cancer can be breast cancer, skin cancer, liver cancer, prostate cancer, ovary cancer, colon cancer, stomach cancer or pancreas cancer.

    Human iNKT cell activation using glycolipids with altered glycosyl groups
    16.
    发明专利
    Human iNKT cell activation using glycolipids with altered glycosyl groups 未知

    公开(公告)号：AU2014317889A1

    公开(公告)日：2016-03-17

    申请号：AU2014317889

    申请日：2014-09-08

    Applicant: ACADEMIA SINICA

    Inventor： WONG CHI-HUEY ,  YU ALICE L ,  LIN KUN-HSIEN ,  WU TAI-NA

    IPC: A61K35/14 ,  A61K31/7012 ,  A61K31/739

    Abstract: Glycosphingolipids (GSLs) bearing α-glucose (α-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with α-glucose (α-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with α-galactose (α-Gal) are disclosed. GSLs bearing α-glucose (α-Glc) and derivatives of α-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with α-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with α-Glc and derivatives thereof are provided.

Patent Agency Ranking